Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

被引:53
|
作者
Chen, Qingyong [1 ]
Fei, Jun [1 ]
Wu, Lijun [1 ]
Jiang, Zhongyong [1 ]
Wu, Yuquan [1 ]
Zheng, Yun [1 ]
Lu, Guohua [2 ]
机构
[1] 117th Hosp PLA, Dept Resp Dis, Hangzhou 310013, Zhejiang, Peoples R China
[2] Zhejiang Univ, Dept Resp Dis, Affiliated Hosp 1, Coll Med, Hangzhou 310004, Zhejiang, Peoples R China
关键词
cathepsin B; cathepsin L; cysteine C; urokinase plasminogen activator; urokinase plasminogen activator receptor; lung cancer; progonosis; sera; INHIBITORS STEFIN-A; PROGNOSTIC-SIGNIFICANCE; PULMONARY ADENOCARCINOMAS; CLINICAL-SIGNIFICANCE; CYSTEINE PROTEINASES; COLORECTAL-CANCER; EXPRESSION; METASTASIS; PROTEASES; PROGRESSION;
D O I
10.3892/ol.2011.302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to determine the levels of cathepsin B (cath B), cathepsin L (cath L), cystatin C, urokinase plasminogen activator (u-PA) and urokinase plasminogen activator receptor (u-PAR) in the sera of patients with lung cancer compared to healthy controls using ELISA. Concomitantly, the relationship between the components and clinicopathological prognosis was analyzed. The study included 30 healthy volunteers and 105 lung cancer patients. Blood samples were collected and cath B, cath L, cystatin C, u-PA and u-PAR measurements were made using ELISA. Results showed that the levels of cath B, cath L, cystatin C, u-PA and u-PAR were significantly higher in the patient group compared to the healthy controls. The significance was marked for cath B and mild for u-PAR in correlation with lymph node metastasis. There was no significance for other parameters. Notably, patients with a combination of high cystatin C and high cath B levels had significantly lower survival probability as compared to those with cystatin C(+)/cath B(-) or with cystatin C(-)/cath B(-), Similarly, patients with a combination of high u-PA and u-PAR experienced significantly shorter survival., Furthermore, the univariate analysis revealed that cath B, u-PAR, lymph node metastases, stage and grade were related to survival. However, findings of the multivariate Cox analysis indicated that the sera levels of cath B, u-PAR and lymph node metastases may serve as independent prognostic variables in patients with lung cancer.
引用
收藏
页码:693 / 699
页数:7
相关论文
共 50 条
  • [41] Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer
    Escot, C
    Zhao, Y
    Puech, C
    Rochefort, H
    BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (02) : 217 - 226
  • [42] Measurement of soluble urokinase plasminogen activator receptor in serum
    Riisbro, R
    Piironen, T
    Brünner, N
    Larsen, B
    Nielsen, HJ
    Stephens, RW
    Hoyer-Hansen, G
    JOURNAL OF CLINICAL LIGAND ASSAY, 2002, 25 (01): : 53 - 56
  • [43] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 I IN BREAST-CANCER CELLS
    WAJIMA, T
    DEGEN, D
    ORIZ, V
    VONHOFFOLIN, DD
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1284 - 1284
  • [44] Dietary predictors of circulating urokinase plasminogen activator receptor
    Drake, I.
    Schulz, C. A.
    Ericson, U.
    Nilsson, J.
    Melander, O.
    Engstrom, G.
    Orho-Melander, M.
    DIABETOLOGIA, 2016, 59 : S52 - S52
  • [45] Crystal structure of the human urokinase plasminogen activator receptor
    Llinas, P
    Le Du, MH
    Gårdsvoll, H
    Dano, K
    Gilquin, B
    Stura, EA
    Ménez, A
    Ploug, M
    THROMBOSIS AND HAEMOSTASIS, 2005, 93 (04) : A8 - A8
  • [46] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: Correlation with tumor associated macrophage and prognosis
    Ohba, K
    Miyata, Y
    Kanda, S
    Koga, S
    Hayashi, T
    Kanetake, H
    JOURNAL OF UROLOGY, 2005, 174 (02): : 461 - 465
  • [47] Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer
    Baart, V. M.
    Houvast, R. D.
    de Geus-Oei, L. F.
    Quax, P. H. A.
    Kuppen, P. J. K.
    Vahrmeijer, A. L.
    Sier, C. F. M.
    EJNMMI RESEARCH, 2020, 10 (01)
  • [48] The behaviour of urokinase type plasminogen activator receptor in gastric cancer.
    Herszenyi, L
    Farinati, F
    Plebani, M
    Carraro, P
    DePaoli, M
    Roveroni, G
    Naccarato, R
    Tulassay, Z
    GASTROENTEROLOGY, 1997, 112 (04) : A576 - A576
  • [49] The Urokinase Receptor Promotes Cancer Metastasis Independently of Urokinase-Type Plasminogen Activator in Mice
    Jo, Minji
    Takimoto, Shinako
    Montel, Valerie
    Gonias, Steven L.
    AMERICAN JOURNAL OF PATHOLOGY, 2009, 175 (01): : 190 - 200
  • [50] IMMUNOHISTOCHEMICAL DETECTION OF THE RECEPTOR FOR UROKINASE PLASMINOGEN-ACTIVATOR IN HUMAN COLON-CANCER
    PYKE, C
    RALFKIAER, E
    RONNE, E
    HOYERHANSEN, G
    KIRKEBY, L
    DANO, K
    HISTOPATHOLOGY, 1994, 24 (02) : 131 - 138